Stem Cell Research Enhancement Act of 2009

Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act, and FY 2011 Financial Services and General Government Appropriations bill; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Policy HR873, S487 Stem Cell Research Enhancement Act of 2009 HR4204, S1857 Enhanced Act of 2009

Client expense: $120,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

HR 1704/S. 682, The Mental Health on Campus Improvement Act, entire bill. HR 872, Stem Cell Research Improvement Act of 2009, entire bill. HR 873/S. 487, Stem Cell Research Enhancement Act of 2009, entire bill. S. 973/HR 2251, Resident Physician Shortage Reduction Act, entire bill.

Client expense: $130,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Enhancement Act of 2009 HR 872, H.R. 873 S 487 National Institutes of Health Clinical Trials Registry National Children's Study Agency For Health Care Research and Quality HR 1549/S. 619 Preservation of Antibiotics of Medical Treatment Act Preemie Act HR 2184 Enhanced Health Care Value For All Act S. 353/HR 758Minority Health Improvement and Health Disparity Elimination Act HR 3525/S.467 FACT Act Pediatric Research Consortia Establishment Act Antimicrobial Resistance/Animal Drug User Fees Act HR 3697/S.2313 Strategies to Address Antimicrobial Resistance Act SCHIP Reauthorization Inclusion of children in NIH clinical trials

Client expense: $56,833 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Consumer Product Safety Commission (CPSC), Education, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Indian Health Service, Labor, Dept of (DOL), Natl Highway Traffic Safety Administration (NHTSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Transportation, Dept of (DOT), Treasury, Dept of, White House Office

Stem Cell Research Improvement Act of 2009 allows for federal funding of embryonic stem cell research provided that certain ethical requirements are met (HR 873 and S 487). Supported the Cord Blood Education and Awareness Acts (H.R. 2107) inclusion in legislation being drafted to reauthorize the C.W. Young Cell Transplantation Program. H.R. 2107 would require uniform and medically accurate information to be developed by the Department of Health and Human Services and disseminated by maternal healthcare providers. Supported HR 1362 for MS and Parkinsons research.

Client expense: $80,000 · Firm income: Not reported

Government targets: AMTRAK - Natl Railroad Passenger Corporation, Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Social Security Administration (SSA), Veterans Affairs, Dept of (VA)

Stem Cell Research Policy HR873, S487 Stem Cell Research Enhancement Act of 2009 HR4204, S1857 Enhanced Act of 2009

Client expense: $70,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

H.R. 3668/ S. 3058, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and The Special Diabetes Program for Indians H.R. 873/S.487, Stem Cell Reserach Enhancement Act of 2009 H.R. 872, Stem Cell Reserach Improvement Act of 2009

Client expense: $220,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1704/S. 682, The Mental Health on Campus Improvement Act, entire bill H.R. 872, Stem Cell Research Improvement Act of 2009, entire bill H.R. 873/S. 487, Stem Cell Research Enhancement Act of 2009, entire bill S. 973/H.R. 2251, Resident Physician Shortage Reduction Act, entire bill H.R. 3200, America's Affordable Health Choices Act, Title III, Subtitle B, Title IV, Title III, Promoting Primary Care; Title IV - Quality, Subtitle A, Subtitle D, Title V - Medicare Graduate Medical Education S. 1679, Affordable Health Choices Act, Title XXXI, Part VIII, Subtitle G - Health IT; Title II - Improving the Quality and Efficiency of Health Care; Title XXXIII, Part T - Employer-Based Wellness Program, Title IV - Health Care Workforce, Sec. 423; Title IV, Subtitle D; Title VI - Improving access to innovative medical therapies H.R. 3590, Patient Protection and Affordable Health Care Act, entire bill H.R. 3692, Affordable Health Care for America Act, entire bill H. Res. 1004/S. Res. 394 - Congratulating the Northwestern University Feinberg School of Medicine for its 150 years of commitment to advancing science and improving health H.R. 4851, Continuing Extension Act of 2010, provision addressing Medicare physician payment cuts H.R. 3962, to provide affordable, quality health care for all Americans and reduce the growth in health care spending, Medicare physician payment cuts provision

Client expense: $140,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; 340 B Program including H.R. 4213, American Jobs and Closing Tax Loopholes Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Improvement Act of 2009 allows for federal funding of embryonic stem cell research provided that certain ethical requirements are met (HR 873 and S 487).

Client expense: $80,000 · Firm income: Not reported

Government targets: AMTRAK - Natl Railroad Passenger Corporation, Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Social Security Administration (SSA), Veterans Affairs, Dept of (VA)

Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; H.R. 3590, Patient Protection and Affordable Care Act. Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Comparative effectiveness including S. 1213, Patient-Centered Outcomes Research Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Health care reform including H.R. 3200, America's Affordable Health Choices Act; S. , Affordable Health Choices Act; and S. , America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010. Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1704/S. 682, The Mental Health on Campus Improvement Act, entire bill H.R. 872, Stem Cell Research Improvement Act of 2009, entire bill H.R. 873/S. 487, Stem Cell Research Enhancement Act of 2009, entire bill S. 973/H.R. 2251, Resident Physician Shortage Reduction Act, entire bill H.R. 3200, America's Affordable Health Choices Act, Title III, Subtitle B, Title IV, Title III, Promoting Primary Care; Title IV - Quality, Subtitle A, Subtitle D, Title V - Medicare Graduate Medical Education S. 1679, Affordable Health Choices Act, Title XXXI, Part VIII, Subtitle G - Health IT; Title II - Improving the Quality and Efficiency of Health Care; Title XXXIII, Part T - Employer-Based Wellness Program, Title IV - Health Care Workforce, Sec. 423; Title IV, Subtitle D; Title VI - Improving access to innovative medical therapies H.R. 3590, Patient Protection and Affordable Health Care Act, entire bill H.R. 3962, Affordable Health Care for America Act, entire bill H.Res. 1004/S.Res. 394 - Congratulating the Northwestern University Feinberg School of Medicine for its 150 years of commitment to advancing science and improving health

Client expense: $140,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Enhancement Act of 2009 HR 872, H.R. 873 S 487 National Institutes of Health Clinical Trials Registry National Children's Study Agency For Health Care Research and Quality HR 1549/S. 619 Preservation of Antibiotics of Medical Treatment Act Preemie Act HR 2184 Enhanced Health Care Value For All Act S. 353/HR 758Minority Health Improvement and Health Disparity Elimination Act HR 3525/S.467 FACT Act Pediatric Research Consortia Establishment Act Antimicrobial Resistance/Animal Drug User Fees Act HR 3697/S.2313 Strategies to Address Antimicrobial Resistance Act SCHIP Reauthorization Inclusion of children in NIH clincial trials

Client expense: $91,142 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Consumer Product Safety Commission (CPSC), Education, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Indian Health Service, Labor, Dept of (DOL), Natl Highway Traffic Safety Administration (NHTSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, White House Office

Stem Cell Research Policy HR873, S487 Stem Cell Research Enhancement Act of 2009 Medicaid GME Policy in the Labor HHS Appropriations Bill (disclosed under BUD) HR4204, S1857 Enhanced Act of 2009

Client expense: $90,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

H.R. 873 / S.487, Stem Cell Research Enhancement Act H.R. 877, Patients First Act of 2009 H.R. __/ S.__, National Diabetes Coordinator Act Health Care Reform Legislation

Client expense: $10,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Improvement Act of 2009 allows for federal funding of embryonic stem cell research provided that certain ethical requirements are met (HR 873 and S 487).

Client expense: $60,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE, Social Security Administration (SSA), Veterans Affairs, Dept of (VA)

Stem Cell Research Improvement Act of 2009 allows for federal funding of embryonic stem cell research provided that certain ethical requirements are met (HR 873 and S 487).

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Social Security Administration (SSA), Treasury, Dept of, Veterans Affairs, Dept of (VA)

H.R. 1704/S. 682, The Mental Health on Campus Improvement Act, entire bill H.R. 872, Stem Cell Research Improvement Act of 2009, entire bill H.R. 873/S. 487, Stem Cell Research Enhancement Act of 2009, entire bill S. 973/H.R. 2251, Resident Physician Shortage Reduction Act, entire bill H.R. 3200, America's Affordable Health Choices Act, Title III, Subtitle B, Title IV, Title III, Promoting Primary Care; Title IV - Quality, Subtitle A, Subtitle D, Title V - Medicare Graduate Medical Education S. 1679, Affordable Health Choices Act, Title XXXI, Part VIII, Subtitle G - Health IT; Title II - Improving the Quality and Efficiency of Health Care; Title XXXIII, Part T - Employer-Based Wellness Program; Title IV - Health Care Workforce, Sec. 423; Title IV, Subtitle D; Title VI - Improving access to innovative medical therapies H.R. 3590, Patient Protection and Affordable Health Care Act, entire bill H.R. 3962, Affordable Health Care for America Act, entire bill

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Policy HR873, S487 Stem Cell Research Enhancement Act of 2009 Medicaid GME Policy in the Labor HHS Appropriations Bill (disclosed under BUD) HR4204, S1857 Enhanced Act of 2009

Client expense: $80,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Health care reform including H.R. 3200, America's Affordable Health Choices Act; S. , Affordable Health Choices Act; and S. , America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3668/S._, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and The Special Diabetes Program for Indians H.R. 3200/S. 1796, America's Healthy Future Act of 2009 H.R. 3590, The Patient Protection and Affordable Care Act H.R. 873/S.487, Stem Cell Research Enhancement Act of 2009 H.R. 872, Stem Cell Reasearch Improvement Act of 2009

Client expense: $20,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Enhancement Act of 2009 HR 872, H.R. 873 S 487 National Institutes of Health Clinical Trials Registry National Children's Study Agency For Health Care Research and Quality HR 1549/S. 619 Preservation of Antibiotics of Medical Treatment Act Preemie Act HR 2184 Enhanced Health Care Value For All Act S. 353/HR 758Minority Health Improvement and Health Disparity Elimination Act HR 3525/S.467 FACT Act Pediatric Research Consortia Establishment Act Antimicrobial Resistance/Animal Drug User Fees Act HR 3697/S.2313 Strategies to Address Antimicrobial Resistance Act SCHIP Reauthorization Inclusion of children in NIH clincial trials

Client expense: $74,075 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Consumer Product Safety Commission (CPSC), Education, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Indian Health Service, Labor, Dept of (DOL), Natl Highway Traffic Safety Administration (NHTSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, White House Office

Stem Cell Research Enhancement Act (H.R. 873/S. 487) / Embryonic Stem Cell Research Bone Marrow Failure Disease Research and Treatment Act (H.R. 1230) Health Reform Legislation: America's Affordable Health Choices Act of 2009 (H.R. 3200) /Affordable Health Care for America Act (H.R. 3962) / Patient Protection and Affordable Care Act (H.R. 3590) Physician Payments Sunshine Act (S. 301) General Hematology Public Health and Research Issues Hematology and Oncology Drug Research and Approval Issues Comparative Effectiveness Research (CER) Sickle Cell Disease Public Access Thrombosis Electronic Health Records (EHRs) Hematology/Oncology Treatment Issues Clinical Trials Insurance Coverage

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), President of the U.S., SENATE

Stem Cell Research Improvement Act of 2009 allows for federal funding of embryonic stem cell research provided that certain ethical requirements are met (HR 873 and S 487).

Client expense: $70,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE, Social Security Administration (SSA), Veterans Affairs, Dept of (VA)

Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Health care reform including H.R. 3200, America's Affordable Health Choices Act; S.___, Affordable Health Choices Act; and S.___, America's Healthy Future Act; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1628/H.R. 3648--Rural Physician Pipeline Act of 2009 (Requested support for the bills) S. 1009: Medicare Care Transitions Program Act of 2009 (Sent letter to Senator Max Baucus requesting language from the bill be incorporated in the final health care reform bill) S. 1239/H.R. 444--340B Program Improvement and Integrity Act of 2009 (Requested support for the bills) H.R. 3200--America's Affordable Health Choices Act of 2009 (Lobbied against cuts to Medicare physician reimbursement rates; requested support from House against amendment to include an Independent Medicare Advisory Committee) H.R. 1715--Protection for Participants in Research Act of 2009 (Worked with House on amendments to bill) H.R. 873--Stem Cell Research Enhancement Act of 2009 (Requested support for bill)

Client expense: $234,199 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)

H.R. 3668/S._, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and The Special Diabetes Program for Indians H.R. 873/ S. 487, Stem Cell Research Enhancement Act of 2009 H.R. 872, Stem Cell Research Improvement Act of 2009 H.R._/S._, National Diabetes Coordinator Act H.R. 3200, S._, Health care Reform

Client expense: $10,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Enhancement Act of 2009 HR 872, H.R. 873 S 487 National Institutes of Health Clinical Trials Registry National Children's Study Agency For Health Care Research and Quality HR 1549/S. 619 Preservation of Antibiotics of Medical Treatment Act Preemie Act HR 2184 Enhanced Health Care Value For All Act S. 353/HR 758Minority Health Improvement and Health Disparity Elimination Act HR 3525/S.467 FACT Act Pediatric Research Consortia Establishment Act Antimicrobial Resistance/Animal Drug User Fees Act HR 3697/S.2313 Strategies to Address Antimicrobial Resistance Act SCHIP Reauthorization

Client expense: $57,797 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Consumer Product Safety Commission (CPSC), Education, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Indian Health Service, Labor, Dept of (DOL), Natl Highway Traffic Safety Administration (NHTSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, White House Office

Stem Cell Research Policy HR873, S487 Stem Cell Research Enhancement Act of 2009 Medicaid GME Policy in the Labor HHS Appropriations Bill (disclosed under BUD)

Client expense: $70,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Stem Cell Research Enhancement Act (H.R.873/S.487) / Embryonic Stem Cell Research Bone Marrow Failure Disease Research and Treatment Act (H.R.1230) Health Reform Legislation/ America's Affordable Health Choices Act of 2009 (H.R.3200) /Affordable Health Choices Act (S.1679) Physician Payments Sunshine Act (S.301) General Hematology Public Health and Research Issues Hematology and Oncology Drug Research and Approval Issues Comparative Effectiveness Research (CER) Sickle Cell Disease Public Access Thrombosis Use of Cesium-137 Chloride Sources in Biomedical Research

Client expense: $30,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

H.R.872, to amend the Public Health Service Act to provide for human embryonic stem cell research H.R.873, to amend the Public Health Service Act to provide for human embryonic stem cell research

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1704/S. 682, The Mental Health on Campus Improvement Act, entire bill H.R. 872, Stem Cell Research Improvement Act of 2009, entire bill H.R. 873/S. 487, Stem Cell Research Enhancement Act of 2009, entire bill S. 973/H.R. 2251, Resident Physician Shortage Reduction Act, entire bill H.R. 3200, America's Affordable Health Choices Act, Title III, Subtitle B, Title IV, Title III, Promoting Primary Care; Title IV - Quality, Subtitle A, Subtitle D, Title V - Medicare Graduate Medical Education S. 1679, Affordable Health Choices Act, Title XXXI, Part VIII, Subtitle G - Health IT; Title II - Improving the Quality and Efficiency of Health Care; Title XXXIII, Part T - Employer-Based Wellness Program; Title IV - Health Care Workforce, Sec. 423; Title IV, Subtitle D; Title VI - Improving access to innovative medical therapies

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Dept. of Labor, HHS, Education and Related Agencies Approps; DoD Approps.; Dept. of Agriculture Appropriations.; H.R. 2920, H.R.873/S.487, Stem Cell Research Enhancement Act of 2009; H.R. 872, Stem Cell Research Improvement Act of 2009; H.R._/S._, National Diabetes Coordinator Act; H.R.3668/S._; Reauthorization of the Special Statutory Funding Prog. for Type 1 Diabetes Research and Special Diabetes Program for Indians; Health Care Reform Legislation

Client expense: Not reported · Firm income: Not reported

Dept. of Labor, HHS, Education and Related Agencies Approps; DoD Approps.; Dept. of Agriculture Appropriations.; H.R. 2920, H.R.873/S.487, Stem Cell Research Enhancement Act of 2009; H.R. 872, Stem Cell Research Improvement Act of 2009; H.R._/S._, National Diabetes Coordinator Act; H.R.3668/S._; Reauthorization of the Special Statutory Funding Prog. for Type 1 Diabetes Research and Special Diabetes Program for Indians; Health Care Reform Legislation

Client expense: Not reported · Firm income: Not reported

Dept. of Labor, HHS, Education and Related Agencies Approps; DoD Approps.; Dept. of Agriculture Appropriations.; H.R. 2920, H.R.873/S.487, Stem Cell Research Enhancement Act of 2009; H.R. 872, Stem Cell Research Improvement Act of 2009; H.R._/S._, National Diabetes Coordinator Act; H.R.3668/S._; Reauthorization of the Special Statutory Funding Prog. for Type 1 Diabetes Research and Special Diabetes Program for Indians; Health Care Reform Legislation

Client expense: Not reported · Firm income: Not reported

Issues relating to the biotechnology industry. Worked on HR 873/ S 487, the Stem Cell Research Enhancement Act of 2009; HR 872 The Stem Cell Research Improvement Act of 2009.

Client expense: Not reported · Firm income: $100,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Improvement Act of 2009 allows for federal funding of embryonic stem cell research provided that certain ethical requirements are met (HR 873 and S 487).

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Social Security Administration (SSA)

Licensing of University Intellectual Property: The Patent Reform Act of 2007 (HR 1260/S 515); Use of Animals in Research: Great Apes Protection Act (HR 5852); Stem Cell Research: Stem Cell Research Enhancement Act of 2009 (HR 873/S 487), Stem Cell Research Improvement Act of 2009 (HR 872).

Client expense: $210,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Stem Cell Research Improvement Act of 2009 allows for federal funding of embryonic stem cell research provided that certain ethical requirements are met (HR 873 and S 487).

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Social Security Administration (SSA)

H.R. 758/S. 353--Pediatric Research Consortia Establishment Act (Requested support for the bills) H.R. 873/S. 487--Stem Cell Research Enhancement Act of 2009 (Requested support for the bills) H.R. 2/S. 275--Childrens Health Insurance Program Reauthorization Act of 2009 (Requested support for the bills) S.1239/H.R. 444: 340B Program Improvement and Integrity Act of 2009 (Requested support for the bills) S. 973/H.R. 2251: The Resident Physician Shortage Reduction Act of 2009 (Requested support for the bills) Advocated for increase in Title VII funding Asked for rescission of Medicare Capital IME Rule Sent letter to request full funding for the National Cord Blood Inventory (NCBI) S. 1009: Medicare Care Transitions Program Act of 2009

Client expense: $272,724 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1704/S. 682, The Mental Health on Campus Improvement Act, entire bill H.R. 872, Stem Cell Research Improvement Act of 2009, entire bill H.R. 873/S. 487, Stem Cell Research Enhancement Act of 2009, entire bill S. 973/H.R. 2251, Resident Physician Shortage Reduction Act, entire bill (no bill #) Affordable Health Choices Act, workforce provisions

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Stem Cell Research Policy HR873, S487 Stem Cell Research Enhancement Act of 2009

Client expense: $85,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

H.R. 872, To amend the Public Health Service Act to provide for human embryonic stem cell research H.R. 873, To amend the Public Health Service Act to provide for human embryonic stem cell research S. 487, A bill to amend the Public Health Service Act to provide for human embyronic stem cell research

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 873/S.487, Stem Cell Research Enhancement Act of 2009 H.R. 872, Stem Cell Research Improvement Act of 2009 H.R._/S._, National Diabetes Coordinator Act H.R._/S._, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and the Special Diabetes Program for Indians Health Care Reform Legislation

Client expense: $160,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug safety and drug counterfeiting including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; Physician payment disclosure including S. 301, Physician Payments Sunshine Act of 2009; Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009; Health information technology including H.R. 1, the American Recovery and Reinvestment Act; Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act; Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; Health care reform including the Affordable Health Choices Act; Stem cell research including S. 487/H.R. 873, Stem Cell Research Enhancement Act of 2009; Prescription drug advertising; Federal preemption for prescription drugs; and Legislation concerning civil litigation including S. 357, Sunshine in Litigation Act of 2009.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE